Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Ronkainen, Hanna ^a   Hirvikoski, Pasi ^b   Kauppila, Saila ^c   Vuopala, Katri S ^d   Paavonen, Timo K ^e   Selander, Katri S ^c,f   Vaarala, Markku H ^a,c  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b Lansi Pohja Central Hospital   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d LAPLAND CENTRAL HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f Heerskink School of Medicine   (United States)

Author keywords

prognosis; renal cell carcinoma; toll like receptor 9; tumour necrosis

Indexed keywords

TOLL LIKE RECEPTOR 9; TLR9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; CANCER GRADING; CANCER STAGING; ENZYME IMMUNOASSAY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOLL-LIKE RECEPTOR 9; TUMOR MARKERS, BIOLOGICAL;

EID: 80052851576     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-84     Document Type: Article

References (36)

1. The changing natural history of renal cell carcinoma. Pantuck AJ, Zisman A, Belldegrun AS, J Urol 2001 166 5 1611 1623 10.1016/S0022-5347(05)65640-6 11586189
2. Prognostic factors and molecular markers for renal cell carcinoma. Bui MH, Zisman A, Pantuck AJ, Han KR, Wieder J, Belldegrun AS, Expert Rev Anticancer Ther 2001 1 4 565 575 10.1586/14737140.1.4.565 12113089 (Pubitemid 34679448)
3. Recognition of pathogen-associated molecular patterns by TLR family. Akira S, Hemmi H, Immunol Lett 2003 85 2 85 95 10.1016/S0165-2478(02)00228-6 12527213 (Pubitemid 36071561)
4. The immunobiology of the TLR9 subfamily. Wagner H, Trends Immunol 2004 25 7 381 386 10.1016/j.it.2004.04.011 15207506 (Pubitemid 38780955)
5. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. Nishiya T, DeFranco AL, J Biol Chem 2004 279 18 19008 19017 10.1074/jbc. M311618200 14976215 (Pubitemid 38623331)
6. TLR9 is localized in the endoplasmic reticulum prior to stimulation. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM, J Immunol 2004 173 2 1179 1183 15240708 (Pubitemid 38924294)
7. A novel Toll-like receptor that recognizes vesicular stomatitis virus. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, Yang J, Fu S, Zhang D, J Biol Chem 2011 286 6 4517 4524 10.1074/jbc.M110.159590 21131352
8. Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. Chang YJ, Wu MS, Lin JT, Chen CC, J Immunol 2005 175 12 8242 8252 16339564
9. Human lung cancer cells express functionally active Toll-like receptor 9. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T, Respir Res 2005 6 1 10.1186/1465-9921-6-1 15631627 (Pubitemid 41357885)
10. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS, Mol Cancer Res 2006 4 7 437 447 10.1158/1541-7786.MCR-06-0007 16849519 (Pubitemid 44197039)
11. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS, Prostate 2007 67 7 774 781 10.1002/pros.20562 17373717 (Pubitemid 46709446)
12. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Muller-Holzner E, Jones A, Widschwendter M, Cancer Sci 2010 101 4 1059 1066 10.1111/j.1349-7006.2010.01491.x 20156214
13. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Vaisanen MR, Vaisanen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, Vaarala MH, Prostate 2010 70 8 817 824 10.1002/pros.21115 20054821
14. Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Papadimitraki ED, Tzardi M, Bertsias G, Sotsiou E, Boumpas DT, Lupus 2009 18 9 831 835 10.1177/0961203309103054 19578108
15. Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Summers SA, Steinmetz OM, Ooi JD, Gan PY, O'Sullivan KM, Visvanathan K, Akira S, Kitching AR, Holdsworth SR, Am J Pathol 2010 177 5 2234 2244 10.2353/ajpath.2010.100153 20847283
16. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. Summers SA, Hoi A, Steinmetz OM, O'Sullivan KM, Ooi JD, Odobasic D, Akira S, Kitching AR, Holdsworth SR, J Autoimmun 2010 35 4 291 298 10.1016/j.jaut.2010.05.004 20810248
17. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM, Clin Genitourin Cancer 2009 7 3 58 65 10.3816/CGC.2009.n.025 19815483
18. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma. Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J, Hirvikoski P, Oncol Rep 2009 21 6 1519 1523 19424632
19. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma. Ronkainen H, Hirvikoski P, Kauppila S, Vaarala MH, Oncol Rep 2011 25 1 129 133 21109967
20. TNM Classification of Malignant Tumours. 6. UICC, Wiley & Sons, New York 2002
21. Tumours of the Urinary System and Male Genital Organs. IARC, IARC Press, Lyon 2004
22. Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS, J Innate Immun 2008 1 1 59 68 20375566
23. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ, BMC Cancer 2010 10 665 10.1186/1471-2407-10-665 21129170
24. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Tanaka J, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K, Kojima T, Takei Y, Int J Oncol 2010 37 4 805 814 20811701
25. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M, Cancer Res 2010 70 23 9816 9826 10.1158/0008-5472.CAN-10- 1251 20935225
26. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, Wu A, BMC Cancer 2010 10 415 10.1186/1471-2407-10-415 20696081
27. Toll-like receptor and RIG-I-like receptor signaling. Kawai T, Akira S, Ann N Y Acad Sci 2008 1143 1 20 10.1196/annals.1443.020 19076341
28. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. Geiger C, Nossner E, Frankenberger B, Falk CS, Pohla H, Schendel DJ, J Mol Med 2009 87 6 595 612 10.1007/s00109-009-0455-2 19271159
29. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C, Seliger B, Cancer Res 1998 58 18 4090 4095 9751617 (Pubitemid 28440562)
30. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. Vogelzang NJ, Priest ER, Borden L, J Urol 1992 148 4 1247 1248 1404646
31. Tumor biology and prognostic factors in renal cell carcinoma. Finley DS, Pantuck AJ, Belldegrun AS, Oncologist 2011 16 Suppl 2 4 13 21346035
32. Spontaneous regression of metastatic renal cancer Case report and literature review. Lokich J, Am J Clin Oncol 1997 20 4 416 418 10.1097/00000421-199708000-00020 9256902 (Pubitemid 27329580)
33. Hypoxia-inducible factors as essential regulators of inflammation. Imtiyaz HZ, Simon MC, Curr Top Microbiol Immunol 2010 345 105 120 10.1007/82-2010-74 20517715
34. Signaling pathways in renal cell carcinoma. Banumathy G, Cairns P, Cancer Biol Ther 2010 10 7 658 664 10.4161/cbt.10.7.13247 20814228
35. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK, PLoS One 2007 2 12 1364 10.1371/journal.pone. 0001364 18159247 (Pubitemid 351753480)
36. Changes in intestinal Toll-like receptors and cytokines precede histological injury in a rat model of necrotizing enterocolitis. Liu Y, Zhu L, Fatheree NY, Liu X, Pacheco SE, Tatevian N, Rhoads JM, Am J Physiol Gastrointest Liver Physiol 2009 297 3 442 50 10.1152/ajpgi.00182.2009 19608731